Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction
Ida Gustafsson, MDa,
Christian Torp-Pedersen, MD, PhD, FACC*,
Lars Køber, MD*,
Finn Gustafsson, MDa,
Per Hildebrandt, MD, PhDa on behalf of the Trace Study Group
a Department of Cardiology and Endocrinology, Frederiksberg University Hospital, Frederiksberg, Denmark
* Department of Cardiology, Gentofte University Hospital, Copenhagen, Denmark

View larger version (10K):
[in a new window]
|
Figure 1 Cumulative mortality from all causes for patients with (A) and without (B) diabetes receiving trandolapril or placebo.
|
|

View larger version (11K):
[in a new window]
|
Figure 2 Rate of progression to severe or resistant heart failure for patients with (A) and without (B) diabetes receiving trandolapril or placebo.
|
|
|